The federal agency has approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.
Genetic research is revealing that up to 35% of cerebral palsy cases have an identifiable genetic cause, leading to earlier diagnoses and potential precision medicine treatments. A recent ...
Higher physical activity and lower screen time in childhood were linked to reduced stress and depression in adolescence, according to a Finnish cohort study. Mental health concerns among adolescents ...
Video content above is prompted by the following: 4. How do the treatment options evolve as a child ages? a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, ...
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit.
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) ...
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit. An 8-year-old boy presented to the pediatrician’s office for ...
The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally. The FDA has approved ...
Peter S. Jensen, MD, comments on the challenges primary health care providers may face when it comes to mental health treatment in pediatrics, and provides screening tools to consider to combat these ...
M pneumoniae infection is not a reportable disease, and testing is often not performed in the outpatient setting, limiting estimates of clinical prevalence and delaying recognition of community ...
LIB Therapeutics has announced that the FDA has accepted its biologics license application (BLA) for lerodalcibep, a treatment designed to lower low-density lipoprotein cholesterol (LDL-C) in patients ...
Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease. Both rare pediatric disease and orphan drug designations from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results